VAXART INC. - COMMON

Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates

24 Feb 2022 07:30:01 By Nasdaq GlobeNewswire

Vaxart Appoints Edward Berg as Senior Vice President and General Counsel

14 Feb 2022 07:00:00 By Nasdaq GlobeNewswire

Vaxart to Participate at the H.C. Wainwright BioConnect Virtual Conference

04 Jan 2022 07:00:07 By Nasdaq GlobeNewswire

Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron

16 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Vaxart Announces Acquisition of Second GMP Manufacturing Facility

01 Dec 2021 07:00:02 By Nasdaq GlobeNewswire

Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2021 on November 30, 2021 

23 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart

18 Nov 2021 15:02:00 By Nasdaq GlobeNewswire

Vaxart Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study in Journal of Infectious Diseases

16 Nov 2021 07:00:02 By Nasdaq GlobeNewswire

Vaxart to Participate at Upcoming Conferences

11 Nov 2021 15:01:00 By Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Third Quarter 2021 Financial Results

04 Nov 2021 15:01:00 By Nasdaq GlobeNewswire

Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset

07 Jul 2021 07:00:01 By Nasdaq GlobeNewswire

Vaxart to Present at the SVB Leerink CybeRx Series: Vaccine Forum

07 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Vaxart to Present at the Jefferies Virtual Healthcare Conference

27 May 2021 07:00:01 By Nasdaq GlobeNewswire

Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Dose-Ranging Trial in Elderly Adults

07 May 2021 07:00:00 By Nasdaq GlobeNewswire

Vaxart Announces First Subject Enrolled in Phase 1b Norovirus Boosting Regimen Study

04 May 2021 07:00:01 By Nasdaq GlobeNewswire

New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses

03 May 2021 16:06:20 By Nasdaq GlobeNewswire

Vaxart Reports First Quarter 2021 Financial Results and Provides Business Update

03 May 2021 07:00:02 By Nasdaq GlobeNewswire

Vaxart to Present at the World Vaccine Congress Washington 2021

29 Apr 2021 07:00:01 By Nasdaq GlobeNewswire

Vaxart to Host a Key Opinion Leader Webinar on the Importance of T-Cell Responses for COVID-19 Vaccines

26 Apr 2021 07:00:01 By Nasdaq GlobeNewswire

Vaxart Appoints David Wheadon, M.D., to its Board of Directors

23 Apr 2021 07:00:00 By Nasdaq GlobeNewswire